CURRICULUM VITAE. Fırat University Medical Faculty, Psychiatry Department. Elazıg. Turkey. Elazıg/Turkey. Turkish Republic.
|
|
|
- Erick Johnson
- 8 years ago
- Views:
Transcription
1 CURRICULUM VITAE Personal Details Surname: Kuloglu First Name: Murat Akademic title/ position: Professor Key Qualifications: Schizophrenia, Biological Psychiatry Research Interest: Psychopharmacology International Experience/Collaborations: Contact Details: Work Address: Name of Hospital: Town: Country: Fırat University Medical Faculty, Psychiatry Department Elazıg Turkey Post Code: Phone/Fax: Date of Birth: 1966 Place and Country of Birth: Country of Citizenship: Country of Training: First Language: Languages: Elazıg/Turkey Turkish Republic Turkey Turkish English
2 Akademic Details Faculty/University ( name and address) Fırat University Medical Faculty/Elazıg Date of Graduation: 1989 Postgraduate Training: Ataturk University Medical Faculty, Psychiatry Department SUPERVISOR IN CHARGE OF TRAINING: From 1991 To 1995 Title of thesis: The efficacy of bromocriptine, a dopamine agonist, in the treatment of negative symptoms in schizophrenic patients Academic Experience: Resident Dr. : Specialist Dr. : Assist. Assoc. Prof.: Assoc. Prof. : Assoc. Prof. : Ataturk University Medical Faculty, Psychiatry Department Elazıg Mental Health and Đlness Hospital Fırat University Medical Faculty, Psychiatry Department Fırat University Medical Faculty, Psychiatry Department Elazıg Training and Research Hospital Assist. Clinic. Supervisor : Ankara Ataturk Training and Research Hospital Assoc. Prof. : Fırat University Medical Faculty, Psychiatry Department 2008-Currently Memberships: Turkish Psychiatry Society, Turkish Social Psychiatry Society International Publications
3 Clinical Trials: 1. Kuloğlu, M., M. Atmaca, A.E. Tezcan, A. Ünal, Ö. Geçici, Color and number preferences of patients with psychiatric disorders in Eastern Turkey, Percept Mot Skills, 94, (2002). 2. Kuloğlu, M., M. Atmaca, A.E. Tezcan, Ö. Geçici, H. Tunçkol, B. Üstündağ, Antioxidant enzyme activities and malondialdehyde levels in patients with obsessive compulsive disorder, Neuropsychobiology, 46, (2002). 3. Kuloğlu, M., M. Atmaca, A.E. Tezcan, B. Üstündağ, S. Bulut, Antioxidant enzyme and malondialdehyde levels in patients with panic disorder, Neuropyschobiology, 46, (2002). 4. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, Ö Gecici, B. Firidin, Serum leptin and cholesterol values in the suicide attempters, Neuropsychobiology, 45, (2002). 5. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, Serum cholesterol and leptin values in patients with borderline personality disorder, Neuropsychobiology, 45, (2002). 6. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, Weight gain and serum leptin levels in patients on lithium treatment, Neuropsychobiology, 46, 67-9 (2002). 7. Kuloğlu, M., B. Üstündağ, M. Atmaca, H. Canatan, A.E. Tezcan, N. Çinkılınc, Lipid peroxidation and antioxidant enzyme levels of patients with schizophrenia and bipolar disorder, Cell Biochem Funct, 20, (2002). 8. Kavuncu, V., M. Kuloğlu, A. Kaya, S. Şahin, M. Atmaca, B. Firidin, Bone metabolism and bone mineral density in premenapausal women with mild depression, Yonsei Med J, 43, (2002). 9. Atmaca, M., M. Kuloğlu, A.E. Tezcan, A. Semerciöz, B Üstündağ, A. Ayar, Serum leptine levels in patients with premature ejeculation, Arch Andrology,48, , Atmaca, M., M. Kuloğlu, A.E. Tezcan, S. Önal, B. Üstündağ, Neopterin levels and dexamethasone supression test in posttraumatic stress disorder, Eur Arch Psychiatry Clin Neurosci, 252, (2002). 11. Atmaca, M., M. Kuloğlu, A.E. Tezcan, Sildenafil use in patients with olanzapineinduced erectile dysfunction, Int. J. Impotance Res, 14, (2002). 12. Atmaca, M., M. Kuloğlu, A.E. Tezcan, A. Semerciöz, The efficacy of citalopram in the treatment of premature ejaculation: a placebo controlled study, Int. J. Impotance Res, 14, (2002). 13. Atmaca, M., M. Kuloğlu, A.E. Tezcan, A. Ünal, Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings, Hum. Psychopharmacol. Clin. Exp, 17, (2002).
4 14. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, Serum leptin and cholesterol levels in the patients with bipolar disorder, Neuropyschobiology, 46, (2002). 15. Atmaca, M., M. Kuloğlu, A.E. Tezcan, Ö. Geçici, H. Canatan, Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidolin patients with schizophrenia, Arch. Med. Res, 33, (2002). 16. Atmaca, M., M. Kuloğlu, A.E. Tezcan, Ö Gecici, Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo- controlled study, Int. Clin. Psychopharmacol, 17, (2002). 17. Kuloğlu, M., M. Atmaca, B. Üstündağ, H. Canatan, Ö. Geçici, A.E. Tezcan, Serum iron levels in schizophrenic patients with or without akathisia, Eur. Neuropsychopharmacol, 13, 67-71(2003). 18. Kuloğlu, M., M. Atmaca, A.E. Tezcan, Ö. Geçici, S. Bulut, Sociodemographic and clinical characteristics of patients with conversion disorder in Eastern Turkey, Soc Psychiatr. Psychiatric Epidemiol, 38, (2003). 19. Atmaca, M., M. Kuloğlu, A.E. Tezcan, A. Semerciöz, B. Üstündağ, Serum leptin levels in patients with premature ejaculation before and after citalopram treatment, BJU Int, 91, (2003). 20. Atmaca, M., M. Kuloğlu, A.E. Tezcan, A. Büyükbayram, Switching to tianeptine in patients with antidepressant-induced sexual dysfunction, Hum Psychopharmacol Clin Exp, 18, (2003). 21. Atmaca, M., A.E. Tezcan, M. Kuloğlu, S. Önal, Neopterin production in posttraumatic stress disorder before and after pharmachotherapy, Eur. Arch. Psychiatry Clin. Neurosci, 253, 34-6 (2003). 22. Tezcan, A.E., M. Atmaca, M. Kuloğlu, B. Üstündağ, Free radicals in patients with posttraumatic stress disorder, Eur. Arch. Psychiatry Clin. Neurosci, 253, (2003). 23. Tezcan, A.E., M. Atmaca, M. Kuloğlu, Ö. Geçici, A. Büyükbayram, H. Tutkun, Dissociative disorders in Turkish inpatients with conversion disorder, Comp. Psychiatry, 44, (2003). 24. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, Serum leptin and triglyceride levels in patients on antipsychotic treatment with atypical antipsychotics, J. Clin. Psychiatry, 64, (2003). 25. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, Nizatidine treatment and its relationship with leptin levels in patientts with olanzapine-induced weight gain, Hum. Psychopharmacol. Clin. Exp, 18, (2003). 26. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, Serum leptin and cholesterol levels in schizophrenic patients with and without suicide attempts. Acta Psychiatr Scand. 108, (2003).
5 27. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, N. Kılıç, Nizatidine for the treatment of patients with quetiapine-induced weight gain, Hum Psychopharmacol, 19:37-40 (2004). 28. Atmaca, M., A.E. Tezcan, M. Kuloğlu, B. Üstündağ, H.Tunçkol Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment, Eur Arch Psychiatry Clin. Neurosci, 254, (2004). 29. Atmaca, M., M. Kuloğlu, A.E. Tezcan, A new atypical antipsychotic: quetiapineinduced sexual dysfunctions Int. J. Impotance Res, 1-3 (2004). 30. Atmaca, M., A.E. Tezcan, M. Kuloğlu, B. Üstündağ, Serum leptin levels in obsessivecompulsive disorder, Psychiatry and Clin. Neurosci, 59, (2005). 31. Atmaca, M., A.E. Tezcan, M. Kuloğlu, Ö. Kırtaş, B. Üstündağ, Serum folate and homocysteine levels in patients with obsessive-compulsive disorder, Psychiatry and Clin. Neurosci, 59, (2005). 32. Atmaca, M., A.E. Tezcan, M. Kuloğlu, B. Üstündağ, Plasma nitrate values in patients with obsessive-compulsive disorder, Psychiatry and Clin. Neurosci, 59, (2005). 33. Geçiçi Ö., M. Kuloğlu, M. Atmaca,AE. Tezcan,H. Tunçkol,M. Emül,B. Üstündağ. High serum leptin levels in depressive disorders with atypical features. Psychiatry Clin Neurosci, 59:736-8 (2005). 34. Atmaca M., E. Tezcan, M. Kuloğlu, B. Üstundağ, Ö. Kırtas. The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia. Psychiatry Clin Neurosci, 59: (2005). 35. Kuloğlu, M., Ö.Geçici, M. Atmaca, A. Kalkan, ĐH. Bahçecioğlu, K.Demirdağ, E. Tezcan, SS.Kılıç Hepatitis B and Hepatitis C virus infection in institutionalized schizophrenia and other psychotic disorders patients in Eastern Turkey Neurology Psychiatry and Brain Research 13: (2006). 36. Kuloğlu, M., M. Atmaca, S. Önal, Ö. Geçici, V. Bulut, A.E. Tezcan, Neopterin levels and dexamethasone supression test in obsessive-compulsive disorder, Psychiatry Res, 151: (2007). 37. Çayköylü A., M. Kuloğlu, Ö.Geçici, Đ. Coşkun, Đ. Kırpınar The effects of antidepressant treatment on serum cholesterol and triglyceride levels in depressive patients Neurology Psychiatry and Brain Research 14:13-8 (2007). 38. Atmaca M., M. Kuloğlu, E. Tezcan, B. Üstündağ Serum leptin and cholesterol values in violent and non-violent suicide attempters Psychiatry Res, 158: (2008). 39. Atmaca M., M. Kuloğlu, E. Tezcan, B. Üstündağ Antioxidant enzyme and malondialdehyde levels in patient with social phobia Psychiatry Res, (2008) 159: (2008). Case Reports:
6 40. Atmaca, M., M. Kuloğlu, A. Ünal, A.E. Tezcan, The detergent is circulating in my blood: A case report, Int. J. Psychiatr. Clin. Pract, 6, (2002). 41. Atmaca, M., M. Kuloğlu, A.E. Tezcan, Quetiapine-associated and dose related hypomania in a w1man with schizophrenia, European Psychiatry, 17, 1-2 (2002). 42. Kuloğlu, M., A. Çayköylü, E. Yılmaz, O. Ekinci, A left temporal lobe arachnoid cyst in a patient with schizophrenia-like psychosis: A case report Prog Neuropsychopharmacol Biol Psychiatry, 32, (2008). 43. Çayköylü A.,O. Ekinci, M. Kuloğlu, Improvement from treatment resistant schizoaffective disorder, manic type after stopping heavy caffeine intake: A case report Prog Neuropsychopharmacol Biol Psychiatry, 32, (2008). 44. Çayköylü A., O. Ekinci, Y. Albayrak, M. Kuloğlu, O. Deniz, Arnold-Chiari I malformation association with generalized anxiety disorder: A case report Prog Neuropsychopharmacol Biol Psychiatry, 32, (2008). 45. Kuloğlu, M., A. Çayköylü, O. Ekinci, E. Yılmaz, Lamotrigine-induced obsessional symptoms in a patient with bipolar II disorder: A case report J Psychopharmacol, (2008) Baskıda. 46. A. Çayköylü, O. Ekinci, M. Kuloğlu, O. Deniz, Aripiprazole induced rabbit syndrome: A case report J Psychopharmacol, (2008) in press. Letter to the Editor: 47. Millet, B., M. Leclaire, C. Bourdel, H. Loo, A.E. Tezcan, M. Kuloğlu, Comparison of sociodemographic, clinical and phenomenological charasteristics of Turkish and French patients suffering from obsessive-compulsive disorder, Can. J. Psychiatry, 45, 848 (2000). 48. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, Ö. Geçici, Weight gain, serum leptin and triglyceride levels in the patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol, Schizophrenia Res, 60, (2003). 49. Atmaca, M., A.E. Tezcan, M. Kuloğlu. An open clinical trial of reboxetine in the treatment of social phobia, J. Clin. Psychopharmacol, 23, (2003). 50. Kuloğlu, M., A. Çayköylü, O. Ekinci, D. Bayındırlı, G. Vural, O. Deniz Successful management of depression with reboxetine in a patient who developed parkinsonism related to paroxetine use J Psychopharmacol, (2008) in press. 51. Kuloğlu, M., O. Ekinci, A. Çayköylü, Venlafaxine-associated nocturnal bruxism in a depressive patient succesfully treated with buspirone J Psychopharmacol, (2009) in press. Presentations at International Scientific Meetings
7 1. Akyol, A., A.E. Tezcan, S. Akarsu, M. Kuloğlu, Epilepsy and conversion disorder among children in Elazığ region, 5th Asian and Ocenian Congress of Child Neurology, p.78, Đstanbul, Turkey, Kuloğlu, M., M. Ay, M. Namlı, A.E. Tezcan, Đ. Halifeoğlu, C. Hepgüvendik, Serum calcium levels and cognitive disturbance in tardive dyskinesia, 6th World Congress of Biological Psychiatry, Biological Psychiatry Vol. 142 (suppl) p.180s, Nice, France, Tezcan A.E, M. Atmaca, F. Ülkeroğlu, M. Kuloğlu, C. Karabulut, EEG abnormalities in schizophrenic patients who treated with clozapine 6th World Biological Congress, Biological Psychiatry Vol 142 (suppl) p.44-45s, Nice, France, Kuloğlu, M., M. Namlı, M. Ay, M. Atmaca, A.E. Tezcan, Plasma lipid levels in patients with panic disorder, An International Symposium on Neurophysiological and Neuropsychological Assessment of Mental and Behavioural Disorders, Program and Abstract Book, p.49, Bursa, Turkey, Kuloğlu, M., M. Ay, A.E. Tezcan, M. Namlı, C. Hepgüvendik, Comparison of DST, CPK and basal cortisol levels in negative and positive schizophrenic patients, An International Symposium on Neurophysiological and Neuropsychological Assessment of Mental and Behavioural Disorders, Program and Abstract Book, p.50, Bursa, Turkey, Kuloğlu, M., A.E.Tezcan, M. Atmaca, C. Karabulut, Distribution of psychiatric diagnosis in elderly patients who applied to university hospital, International Psychogeriatric and Turkish Society of Psychogeriatrics. A Joint Meeting, p.41, Đstanbul, Turkey, Kuloğlu, M., A.E. Tezcan, M. Atmaca, M. Namlı, Ö. Geçici, Psychosocial and environmental problems in elderly period psychiatric disorders, International Psychogeriatric and Turkish Society of Psychogeriatrics. A Joint Meeting, p.98, Đstanbul, Turkey, Kuloğlu, M., M.Atmaca, Ö.Geçici, A.E. Tezcan, Terror and internal migration in patients diagnosed as PTSD in Elazığ region, 6th European Conferance on Traumatic Stress, p.140, Đstanbul, Atmaca, M., M. Kuloğlu, E. Tezcan, Ö. Geçici, A, Ünal, B. Firidin. The comparison of quetiapine and haloperidol effects on serum prolactin in patients with schizophrenia, European Neuropsychopharmacology, Vol 11 (suppl 3) p.240s, Atmaca, M., M. Kuloğlu, E. Tezcan, Ö. Geçici, Y, Bayık, A. Ünal, H. Tunçkol. The comorbidity of obsessive compulsive disorder and bipolar disorder, European Neuropsychopharmacology, Vol 11 (suppl 3) p s, 2001.
CURRICULUM VITAE. Personal Details. Surname: OZDEN First name: Mehmet Academic title/position: Assoc. Prof. Key Qualifications: Infection Immunology
CURRICULUM VITAE Personal Details Surname: OZDEN First name: Mehmet Academic title/position: Assoc. Prof. Key Qualifications: Infection Immunology Research Interest: Infectious Diseases International Experience/Collaborations:
The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia
Blackwell Science, LtdOxford, UKPCNPsychiatry and Clinical Neurosciences1323-13162005 Blackwell Science Pty LtdDecember 2005596652656Original ArticleExtract of gingko biloba in schizophreniam. Atmaca et
309.28 F43.22 Adjustment disorder with mixed anxiety and depressed mood Adjustment disorder with disturbance of conduct
Description ICD-9-CM Code ICD-10-CM Code Adjustment reaction with adjustment disorder with depressed mood 309.0 F43.21 Adjustment disorder with depressed mood Adjustment disorder with anxiety 309.24 F43.22
Conjoint Professor Brian Draper
Chronic Serious Mental Illness and Dementia Optimising Quality Care Psychiatry Conjoint Professor Brian Draper Academic Dept. for Old Age Psychiatry, Prince of Wales Hospital, Randwick Cognitive Course
North of Tyne Area Prescribing Committee
North of Tyne Area Prescribing Committee ANTIPSYCHOTICS IN PSYCHOSIS, BIPOLAR DISORDER AND AUGMENTATION THERAPY IN TREATMENT RESISTANT DEPRESSION Information for Primary Care Updated November 2013 This
Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents
These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder,
[KQ 804] FEBRUARY 2007 Sub. Code: 9105
![[KQ 804] FEBRUARY 2007 Sub. Code: 9105](/thumbs/26/8053833.jpg "[KQ 804] FEBRUARY 2007 Sub. Code: 9105")
[KQ 804] FEBRUARY 2007 Sub. Code: 9105 (Revised Regulations) Theory : Two hours and forty minutes Q.P. Code: 419105 Maximum : 100 marks Theory : 80 marks M.C.Q. : Twenty minutes M.C.Q. : 20 marks 1. A
Improving the Recognition and Treatment of Bipolar Depression
Handout for the Neuroscience Education Institute (NEI) online activity: Improving the Recognition and Treatment of Bipolar Depression Learning Objectives Apply evidence-based tools that aid in differentiating
Psychotic Disorder. Psychosis. Psychoses may be caused by: Examples of Hallucinations and Delusions 12/12/2012
Psychosis Psychotic Disorder Dr Lim Boon Leng Psychiatrist and Medical Director Dr BL Lim Centre For Psychological Wellness Tel: 64796456 Email: info@psywellness.com.sg Web: www.psywellness.com.sg A condition
Curriculum Vitae RUDRA PRAKASH, M.D.
1 Archives (Prakash Collection) September 17, 2015 Curriculum Vitae RUDRA PRAKASH, M.D. Office Address: V.A. Medical Center C-303 1310 24 th Avenue, South Nashville, TN 37212 Office: 615-873-7651; Fax
BIPOLAR DISORDER IN PRIMARY CARE
E-Resource January, 2014 BIPOLAR DISORDER IN PRIMARY CARE Mood Disorder Questionnaire Common Comorbidities Evaluation of Patients with BPD Management of BPD in Primary Care Patient resource Patients with
4-Deveci F, Akbulut HH, Çelik I, Muz MH Ilhan F. Lymphocyte Subpopulations in Pulmonary Tuberculosis Patients, Mediators Inflamm., 2006;(2);89070.
CURRICULUM VITAE Personal Details Surname: Muz Frst Name: Mehmet Hamdi Academic title/position: Prof. Dr.- President of Chest Disease Departmant Key Qualifcations: Research Interest: Lung Cancers Đnternational
Chronic mental illness in LTCF. Chronic mental illness. Other psychiatric disorders.
Chronic mental illness in LTCF Abhilash K. Desai MD Medical Director Alzheimer s Center of Excellence Chronic mental illness 1. Schizophrenia and Schizoaffective disorder. 2. Bipolar disorder (Type 1 and
Algorithm for Initiating Antidepressant Therapy in Depression
Algorithm for Initiating Antidepressant Therapy in Depression Refer for psychotherapy if patient preference or add cognitive behavioural office skills to antidepressant medication Moderate to Severe depression
Understanding Antipsychotic Medications
Understanding Antipsychotic Medications NARSAD RESEARCH National Alliance for Research on Schizophrenia and Depression 60 Cutter Mill Road, Suite 404 Great Neck, NY 11021 516-829-0091 1-800-829-8289 516-487-6930
ATYPICALS ANTIPSYCHOTIC MEDICATIONS
The atypical antipsychotics are a class of drugs that are used to treat a number of behavioral health disorders, including schizophrenia, other psychotic disorders, mood disorders, and behavioral agitation
Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness
Barriers to Healthcare Services for People with Mental Disorders Cardiovascular disorders and diabetes in people with severe mental illness Dr. med. J. Cordes LVR- Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität
PSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS. Juanaelena Garcia, MD Psychiatry Director Institute for Family Health
PSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS Juanaelena Garcia, MD Psychiatry Director Institute for Family Health Learning Objectives Learn basics about the various types of medications that
Psychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
Mental Health & Substance Use Disorders
Mental Health & Substance Use Disorders Thank you to Daniella Kanareck Dr. Arielle Taylor Overview 1. Overview of Mental Health 2. Stigma and attitudes associated with this population 3. Mental Disorders
Recognizing and Treating Depression in Children and Adolescents.
Recognizing and Treating Depression in Children and Adolescents. KAREN KANDO, MD Division of Child and Adolescent Psychiatry Center for Neuroscience and Behavioral Medicine Phoenix Children s Hospital
, 332-337 CASE REPORT ARIPIPRAZOLE IN PSYCHOTIC DEPRESSION: FOUR CASE REPORTS Kuppuswami Shivakumar, Amna Mir, Victoria D.M. McAllister, Veronica O Keane, Katherine J. Aitchison Summary Object: Aripiprazole
Crosswalk to DSM-IV-TR
Crosswalk to DSM-IV-TR Note: This Crosswalk includes only those codes most frequently found on existing CDERs. It does not include all of the codes listed in the DSM-IV-TR nor does it include all codes
This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC.
This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC. Indiana University School of Medicine and CME Outfitters, LLC, gratefully acknowledge
Major Depressive Disorder:
Major Depressive Disorder: An Actuarial Commercial Claim Data Analysis July 2013 Prepared by: Milliman, Inc. NY Kate Fitch RN, MEd Kosuke Iwasaki FIAJ, MAAA, MBA This report was commissioned by Takeda
Unit 4: Personality, Psychological Disorders, and Treatment
Unit 4: Personality, Psychological Disorders, and Treatment Learning Objective 1 (pp. 131-132): Personality, The Trait Approach 1. How do psychologists generally view personality? 2. What is the focus
Sleep Medicine and Psychiatry. Roobal Sekhon, D.O.
Sleep Medicine and Psychiatry Roobal Sekhon, D.O. Common Diagnoses Mood Disorders: Depression Bipolar Disorder Anxiety Disorders PTSD and other traumatic disorders Schizophrenia Depression and Sleep: Overview
MEDICATION FOR IMPULSIVE AGGRESSION
MEDICATION FOR IMPULSIVE AGGRESSION 1 Publications Carbamazepine for uncontrolled rage outbursts (1984) Lancet Metoprolol for intermittent explosive disorder (1985) American Journal of Psychiatry Psychopharmacology
Update on guidelines on biological treatment of depressive disorder. Dr. Henry CHEUNG Psychiatrist in private practice
Update on guidelines on biological treatment of depressive disorder Dr. Henry CHEUNG Psychiatrist in private practice 2013 update International Task Force of World Federation of Societies of Biological
Emergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
Bipolar Disorder. Mania is the word that describes the activated phase of bipolar disorder. The symptoms of mania may include:
Bipolar Disorder What is bipolar disorder? Bipolar disorder, or manic depression, is a medical illness that causes extreme shifts in mood, energy, and functioning. These changes may be subtle or dramatic
ICD- 9 Source Description ICD- 10 Source Description
291.0 Alcohol withdrawal delirium F10.121 Alcohol abuse with intoxication delirium 291.0 Alcohol withdrawal delirium F10.221 Alcohol dependence with intoxication delirium 291.0 Alcohol withdrawal delirium
TREATMENT-RESISTANT DEPRESSION AND ANXIETY
University of Washington 2012 TREATMENT-RESISTANT DEPRESSION AND ANXIETY Catherine Howe, MD, PhD University of Washington School of Medicine Definition of treatment resistance Failure to remit after 2
The Maryland Public Behavioral Health System
The Maryland Public Behavioral Health System Arleen Rogan, Ph.D. Division Director, Integrated Health Services Family Services, Inc. Arleen.rogan@fs-inc.org Behavioral Health includes: Mental health conditions
Educational Background 2006-2013 Hacettepe University, Faculty of Medicine, MD-PHD Program, Turkey PHD on Neuroscience
HALE YAPICI ESER, M.D., Ph.D. Address: Koç Üniversitesi Hastanesi Davutpaşa Caddesi No:4 34010 Topkapı, İstanbul-Turkey Phone: +90 850 250 8 250 E-mail: heser@kuh.ku.edu.tr Personal Details Date of Birth
SLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS
E-Resource December, 2013 SLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS Between 10-18% of adults in the general population and up to 50% of adults in the primary care setting have difficulty sleeping. Sleep
PSYCHOTROPIC MEDICATIONS
PSYCHOTROPIC MEDICATIONS 644.3 Bipolar Disorder This Instructor s Guide contains: Brief Description, Objectives, Discussion Questions, Pretest, Post-test, Answer Keys and Glossary for this program, Psychotropic
IL DHS/DMH DSM 5 Diagnoses Effective 10-1-2015 Target Population: Serious Mental Illness (SMI) for DHS/DMH funded MH services
IL DHS/DMH DSM 5 Diagnoses Effective 10-1-2015 Target Population: Serious Mental Illness (SMI) for DHS/DMH funded MH services ICD-10 DSM-V Description F22 Delusional Disorder F23 Brief Psychotic Disorder
placebo-controlledcontrolled double-blind, blind,
Clinical Potential of Minocycline for Depression with Psychotic Features Tsuyoshi Miyaoka Department of Psychiatry Shimane University School of Medicine Minocycline 1. Second-generation tetracycline which
How To Safely Use Aripiprazole
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Bipolar I Disorder Reported prevalence rates for bipolar I disorder differ due to local variations in psychiatric practice, variations
Clinical Practice Guidelines: Attention Deficit/Hyperactivity Disorder
Clinical Practice Guidelines: Attention Deficit/Hyperactivity Disorder AACAP Official Action: OUTLINE OF PRACTICE PARAMETERS FOR THE ASSESSMENT AND TREATMENT OF CHILDREN, ADOLESCENTS, AND ADULTS WITH ADHD
Specialty Mental Health Services OUTPATIENT TABLE
Specialty Mental Health Services Enclosure 3 295.10 Schizophrenia, Disorganized Type F20.1 Disorganized schizophrenia 295.20 Schizophrenia, Catatonic Type F20.2 Catatonic schizophrenia 295.30 Schizophrenia,
DSM IV TR Diagnostic Codes. (In Numeric Order) DSM IV Codes: Through revisions on 10.01.1996 and 10.01.2005. Code Description Code Description
290.0 Dementia of the Alzheimer's type, with late onset, uncomplicated NO DSM IV TR 290 code / See codes [294.10 294.1x] 290.10A Dementia due to Creutzfeldt Jakob disease NO DSM IV TR 290.10 code / See
I. The Positive Symptoms...Page 2. The Negative Symptoms...Page 2. Primary Psychiatric Conditions...Page 2
SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816 SPA PCP Treatment & Referral Guideline Assessment & Treatment of Psychosis Developed March 1, 2003 Revised September 21,
Introduction to the DSM-IV and Psychological Testing
Introduction to the DSM-IV and Psychological Testing Significance of Mental Illness In any given year, how many Americans will suffer with a diagnosable mental illness? How many will suffer with a serious
Provider Notice 1.13. May 30, 2008. Pre-Authorization 1915(b) Service
Provider Notice 1.13 May 30, 2008»» Pre-Authorization 1915(b) Service 1915(b) Attendant Care Services (CPT T1019HE) and 1915(b) Case Conference services (CPT 99366, 99367, 99368) are pre-authorized services
TABLE 6E--REVISED DIAGNOSIS CODE TITLES Page 1 of 9 October 1, 2004
TABLE 6E--REVISED DIAGNOSIS CODE TITLES Page 1 of 9 041.82 Bacteroides fragilis 070.41 Acute hepatitis C with hepatic coma 070.51 Acute hepatitis C without mention of hepatic coma 250.00 Diabetes mellitus
Disclosures Christer Allgulander
How Patients With Generalized Anxiety Disorder (GAD) Are Treated in Specialized Care: A Pharmacoepidemiological Case Register Study in Sweden Christer Allgulander MD, Karolinska Institutet, Sweden Jan
ICD-9/DSM IV TO ICD-10 CROSSWALK TABLE
ICD-9/DSM IV TO ICD-10 CROSSWALK TABLE DIAGNOSIS MEETS OUTPATIENT "MEDICAL NECESSITY" CRITERIA ICD-9 DSM IV Description ICD-10 ICD-10 Description PSYCHOTIC DISORDERS 295.30 Schizophrenia, Paranoid Type
Behavioral Health Diagnoses Not Subject to Visit Limits for Most HMSA Plans
Behavioral Health Diagnoses Not Subject to Visit Limits for Most HMSA Plans ICD-9 295.10 Schizophrenia, disorganized type 295.11 N/A Disorganized type schizophrenia, state Disorganized type schizophrenia,
The management of bipolar disorder in adults, children and adolescents, in primary and secondary care
Quick reference guide Issue date: July 2006 Bipolar disorder The management of bipolar disorder in adults, children and adolescents, in primary and secondary care Developed by the National Collaborating
Bipolar disorder. Understanding NICE guidance
Understanding NICE guidance Information for people who use NHS services Bipolar disorder NICE clinical guidelines advise the NHS on caring for people with specific conditions or diseases and the treatments
PSYC PSYCHOLOGY. 2011-2012 Calendar Proof
PSYC PSYCHOLOGY PSYC1003 is a prerequisite for PSYC1004 and PSYC1004 is a prerequisite for all remaining Psychology courses. Note: See beginning of Section F for abbreviations, course numbers and coding.
Criteria to Identify Abnormal Behavior
Criteria to Identify Abnormal Behavior Unusualness Social deviance Emotional distress Maladaptive behavior Dangerousness Faulty perceptions or interpretations of reality Hallucinations Delusions Copyright
Atypical antipsychotics and the metabolic syndrome. Thomas R. Dekoj, MS3 UIC College of Medicine
Atypical antipsychotics and the metabolic syndrome Thomas R. Dekoj, MS3 UIC College of Medicine Antipsychotic uses Schizophrenia and related d/o ~1% Bipolar ~2% used widely in schizophrenia spectrum d/o,
HIV Case Conference: Use of Anti Psychotics for Non Psychotic Disorders
AM1 F/C AETC Faculty Psych Thursday, June 19, 2014 12:30 1:30pm (EDT) Facilitator Debbie Cestaro Seifer, MS, RN University of South Florida Didactic Presenter Patrick Marsh, MD University of South Florida
Psychotic Disorders. Goals. Goals continued. Goals continued. What is Psychosis? Where does it occur? Provide a working definition for psychosis
Psychotic Disorders Robert W. Marvin, MD Assistant Professor Acting Residency Training Director Department of Psychiatry rwmarvin@uic.edu 1 Goals Provide a working definition for psychosis Understand the
CRITERIA CHECKLIST. Serious Mental Illness (SMI)
Serious Mental Illness (SMI) SMI determination is based on the age of the individual, functional impairment, duration of the disorder and the diagnoses. Adults must meet all of the following five criteria:
Generalised anxiety disorder in adults
www.bpac.org.nz keyword: anxiety Generalised anxiety disorder in adults diagnosis and management Key concepts: Anxiety disorders are the most frequently seen mental disorders in primary care Generalised
CURRICULUM VITAE. Key Qualifications: Gastroenterology, Hepatology, Pancreatobiliary system
CURRICULUM VITAE Personal Details Surname: BAHCECIOGLU First Name: Ibrahim Halil Akademic title/ position: Prof. Dr. Key Qualifications: Gastroenterology, Hepatology, Pancreatobiliary system Research Interest:
Antidepressant treatment in adults
Antidepressant treatment in adults A NICE pathway brings together all NICE guidance, quality standards and materials to support implementation on a specific topic area. The pathways are interactive and
Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of
Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of antipsychotic agents Identify common adverse effects
Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole)
EMA/303592/2015 Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Pharmathen, which details the measures
ÖZGEÇMĐŞ. Araştırma ilgi Alanı: Klinik Biyokimya, Serbest radikaller, Adipositokinler, Diabetes mellitus, Metabolik sendrom
ÖZGEÇMĐŞ Kişisel Bilgiler Soyadı:...ÜSTÜNDAĞ Adı:.... BĐLAL Akademik Unvanı/Görevi: Prof.Dr./Öğretim Üyesi Mesleki ve Profesyonel Anahtar Nitelik ve Becerileri: Araştırma ilgi Alanı: Klinik Biyokimya,
Billing for other services for members in psychiatric residential treatment facilities
Billing for other services for members in psychiatric residential treatment facilities Summary: Psychiatric residential treatment facilities (PRTF) are an all-inclusive treatment program for children and
Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care
Issue date: July 2006 Bipolar disorder The management of bipolar disorder in adults, children and adolescents, in primary and secondary care NICE clinical guideline 38 Developed by the National Collaborating
SUPERVĐSOR ĐN CHARGE OF TRAINING: Şef Dr Kunter Perim
CURRICULUM VITAE Personal Details Surname: Deveci First Name: Figen Academic title/position: Prof, Departmant of Chest Disease Key Qualifcations: Research Interest: Asthma Bronchiale Đnternational Experience/Collaborations:
Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease
Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease Professional Tool #1: Screening and Monitoring in a High-Risk Population: Questions and Answers Overview of Cardiometabolic
Dr.Fatima Kamran. Assistant Professor/ Clinical Psychologist
Dr.Fatima Kamran 650-G, Phase 5, D.H.A, Lahore, Pakistan Home: 00-92-42-35734006 Cell: 00-44-7941095704 f.kamran@surrey.ac.uk, fatimakamran24@yahoo.com Assistant Professor/ Clinical Psychologist University
How To Treat Aphasic Depression
Antipsychotic Use in Patients with Parkinson s Disease 단국의대 정신과 이석범 Difficulties in Parkinson's disease Motor symptoms Neuropsychiatric syndromes Severe Disability Cognitive impairment 2 Neuropsychiatric
Background. Population/Intervention(s)/Comparator/Outcome(s) (PICO)
updated 2012 Role of anticholinergic medications in patients requiring long-term antipsychotic treatment for psychotic disorders Q6: In individuals with psychotic disorders (including schizophrenia) who
Research Update on Schizophrenia
Research Update on Schizophrenia Robert Freedman MD Professor and Chair, Department of Psychiatry University of Colorado Editor, American Journal of Psychiatry Disclosures No financial conflicts of interest
Abnormal Psychology PSY-350-TE
Abnormal Psychology PSY-350-TE This TECEP tests the material usually taught in a one-semester course in abnormal psychology. It focuses on the causes of abnormality, the different forms of abnormal behavior,
Evaluating Dimensions of
Evaluating Dimensions of Geriatric Depression and Anxiety Joel E. Streim, MD Professor, Psychiatry Geriatric Psychiatry Section University of Pennsylvania VISN 4 MIRECC Philadelphia VA Medical Center Philadelphia,
Medication Management of Depressive Disorders in Children and Adolescents. Satya Tata, M.D. Kansas University Medical Center
Medication Management of Depressive Disorders in Children and Adolescents Satya Tata, M.D. Kansas University Medical Center First Line Medications SSRIs Prozac (Fluoxetine): 5-605 mg Zoloft (Sertraline):
Trends in Prescribing of Antipsychotic Drugs in General Practice in England (Chart 1) 2.0. Other second generation antipsychotics (SGA)
Antipsychotic drugs Antipsychotics can be broadly classified into first generation antipsychotics (FGAs, formerly known as typical antipsychotics) and second generation antipsychotics (SGAs, formerly known
DSM 5 AND DISRUPTIVE MOOD DYSREGULATION DISORDER Gail Fernandez, M.D.
DSM 5 AND DISRUPTIVE MOOD DYSREGULATION DISORDER Gail Fernandez, M.D. GOALS Learn DSM 5 criteria for DMDD Understand the theoretical background of DMDD Discuss background, pathophysiology and treatment
Serious Mental Illness: Symptoms, Treatment and Causes of Relapse
Serious Mental Illness: Symptoms, Treatment and Causes of Relapse Bipolar Disorder, Schizophrenia and Schizoaffective Disorder Symptoms and Prevalence of Bipolar Disorder Bipolar disorder, formerly known
Complete List of DSM-IV Codes
Complete List of DSM-IV Codes The following 2 tables give basic codes for all DSM-IV diagnoses. Note that the numbers are the least important part of the diagnoses: Additional verbiage, often not stated
Personality Disorders (PD) Summary (print version)
Personality Disorders (PD) Summary (print version) 1/ Definition A Personality Disorder is an abnormal, extreme and persistent variation from the normal (statistical) range of one or more personality attributes
Psychology Externship Program
Psychology Externship Program The Washington VA Medical Center (VAMC) is a state-of-the-art facility located in Washington, D.C., N.W., and is accredited by the Joint Commission on the Accreditation of
Elderly Patients with Schizophrenia and Depression: Diagnosis and Treatment
Comprehensive Reviews Elderly Patients with Schizophrenia and Depression: Diagnosis and Treatment Kandi Felmet 1, Sidney Zisook 2, John W. Kasckow 1, 3 Abstract Background: The treatment of older patients
Much of our current conceptual
DIAGNOSTIC BOUNDARIES BETWEEN BIPOLAR DISORDER AND SCHIZOPHRENIA: IMPLICATIONS FOR PHARMACOLOGIC INTERVENTION * Stephen M. Strakowski, MD ABSTRACT Schizophrenia and bipolar disorder are distinguished primarily
Treatments for Major Depression. Drug Treatments The two (2) classes of drugs that are typical antidepressants are:
Treatments for Major Depression Drug Treatments The two (2) classes of drugs that are typical antidepressants are: 1. 2. These 2 classes of drugs increase the amount of monoamine neurotransmitters through
Donepezil as a precipitating factor of mania: a case report
Donepezil as a precipitating factor of mania: a case report Jonathan G Leung, PharmD, BCPS, BCPP Psychiatric Clinical Pharmacist Western Psychiatric Institute and Clinic University of Pittsburgh Medical
COMPREHENSIVE MANAGEMENT OF THE ELDERLY PATIENT WITH MANIA
COMPREHENSIVE MANAGEMENT OF THE ELDERLY PATIENT WITH MANIA Manic depressive illness is a biological brain disorder that produces significant alterations of mood and psychosis. Mania in the elderly occurs
Perinatal Mood and Anxiety Disorders
Perinatal Mood and Anxiety Disorders Mother love in infancy and childhood is as important for mental health as are vitamins and proteins for physical health ~ John Bowlby YOU ARE NOT TO BLAME The Spectrum
Mental Health ICD-10 Codes Department of Health and Mental Hygiene
Mental Health ICD-10 Codes Department of Health and Mental Hygiene (2) For dates of service on or after October 1, 2015: F200 F201 F202 F203 F205 F2081 F2089 F209 F21 F22 F23 F24 F250 F251 F258 F259 F28
Men Sexual Dysfunction Associated with Obesity and Metabolic Syndrome
Men Sexual Dysfunction Associated with Obesity and Metabolic Syndrome By Aly A. Abbassy, MD, FACE Professor of Medicine (Endocrinology) Alexandria University My Talk will include: 1-Types of Men sexual
The Diagnostic field. Functions (specialised levels)
Job description: Consultant in psychiatry combined with Clinical professor and Chair. Department for Depression and Anxiety, Aarhus University Hospital Risskov, Denmark. A position as Consultant in psychiatry
Treating Mental Disorders. Types of Biological Treatment. Drug Treatments for Psychological Disorders
Treating Mental Disorders Biological Treatments for Psychological Disorders Aims: Describe and Assess Biological Treatments Objectives By the end of this session you should be able to: Describe the use
BRIEF NOTES ON THE MENTAL HEALTH OF CHILDREN AND ADOLESCENTS
BRIEF NOTES ON THE MENTAL HEALTH OF CHILDREN AND ADOLESCENTS The future of our country depends on the mental health and strength of our young people. However, many children have mental health problems
Disclosure Statement. Nursing Facility Regulations and Psychotropic Medication Use. Learning Objectives (Cont) Learning Objectives
Nursing Facility Regulations and Psychotropic Medication Use Jeffrey C. Reist PharmD, BCPS College of Pharmacy The University of Iowa December 2010 Disclosure Statement I, Jeffrey Reist, PharmD, BCPS do
Top Peer Reviewed Journals Psychiatry & Psychology
Top Peer Reviewed Journals Psychiatry & Psychology Presented to Iowa State University Presented by Thomson Reuters Psychiatry & Psychology The subject discipline for Psychiatry & Psychology is made of
A Manic Episode is defined by a distinct period during which there is an abnormally and persistently elevated, expansive, or irritable mood.
Bipolar disorder Bipolar (manic-depressive illness) is a recurrent mode disorder. The patient may feel stable at baseline level but experience recurrent shifts to an emotional high (mania or hypomania)
CLINICIAN INTERVIEW COMPLEXITIES OF BIPOLAR DISORDER. Interview with Charles B. Nemeroff, MD, PhD
COMPLEXITIES OF BIPOLAR DISORDER Interview with Charles B. Nemeroff, MD, PhD Dr Nemeroff is the Reunette W. Harris Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at Emory
Psychosis Psychosis-substance use Bipolar Affective Disorder Programmes EASY JCEP EPISO Prodrome
Dr. May Lam Assistant Professor, Department of Psychiatry, The University of Hong Kong Psychosis Psychosis-substance use Bipolar Affective Disorder Programmes EASY JCEP EPISO Prodrome a mental state in
Understanding tardive dyskinesia
Understanding tardive dyskinesia 1 Contents What is tardive dyskinesia? 3 What does TD look like? 3 What might affect the risk of me getting TD? 4 Will TD disappear if I stop my medication? 5 What else
Dementa Formulary Guidance [v1.0]
![Dementa Formulary Guidance [v1.0]](/thumbs/29/13622067.jpg "Dementa Formulary Guidance [v1.0]")
Dementa Formulary Guidance [v1.0] 1. Introduction These Guidelines are intended for routine use. However there will be instances where they are not suitable for the patient you are managing, where more
How to Recognize Depression and Its Related Mood and Emotional Disorders
How to Recognize Depression and Its Related Mood and Emotional Disorders Dr. David H. Brendel Depression s Devastating Toll on the Individual Reduces or eliminates pleasure and jo Compromises and destroys